Virios Therapeutics (VIRI) Competitors $5.08 +0.32 (+6.72%) As of 07/14/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock VIRI vs. AQST, HUMA, AMRN, PRTA, BNTC, HRTX, SNDL, VOR, AURA, and ATXSShould you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include Aquestive Therapeutics (AQST), Humacyte (HUMA), Amarin (AMRN), Prothena (PRTA), Benitec Biopharma (BNTC), Heron Therapeutics (HRTX), SNDL (SNDL), Vor Biopharma (VOR), Aura Biosciences (AURA), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical products" industry. Virios Therapeutics vs. Its Competitors Aquestive Therapeutics Humacyte Amarin Prothena Benitec Biopharma Heron Therapeutics SNDL Vor Biopharma Aura Biosciences Astria Therapeutics Aquestive Therapeutics (NASDAQ:AQST) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability. Is AQST or VIRI more profitable? Virios Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -100.02%. Aquestive Therapeutics' return on equity of 0.00% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics-100.02% N/A -50.31% Virios Therapeutics N/A -130.33%-115.00% Which has more risk & volatility, AQST or VIRI? Aquestive Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Which has stronger earnings and valuation, AQST or VIRI? Virios Therapeutics has lower revenue, but higher earnings than Aquestive Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquestive Therapeutics$57.56M6.94-$44.14M-$0.59-6.81Virios TherapeuticsN/AN/A-$5.30M-$0.27-18.81 Does the media prefer AQST or VIRI? In the previous week, Aquestive Therapeutics had 5 more articles in the media than Virios Therapeutics. MarketBeat recorded 5 mentions for Aquestive Therapeutics and 0 mentions for Virios Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.15 beat Virios Therapeutics' score of 0.00 indicating that Aquestive Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aquestive Therapeutics Positive Virios Therapeutics Neutral Do insiders and institutionals hold more shares of AQST or VIRI? 32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 7.9% of Aquestive Therapeutics shares are held by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend AQST or VIRI? Aquestive Therapeutics presently has a consensus target price of $10.14, suggesting a potential upside of 152.31%. Virios Therapeutics has a consensus target price of $5.00, suggesting a potential downside of 1.57%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aquestive Therapeutics is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquestive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryAquestive Therapeutics beats Virios Therapeutics on 11 of the 15 factors compared between the two stocks. Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRI vs. The Competition Export to ExcelMetricVirios TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.99M$762.40M$5.62B$9.30BDividend YieldN/A4.84%4.25%4.03%P/E Ratio-18.811.1828.5719.58Price / SalesN/A25.52424.2194.37Price / CashN/A19.5636.0257.93Price / Book25.406.918.135.54Net Income-$5.30M-$4.17M$3.24B$257.73M7 Day Performance5.83%2.33%2.03%0.95%1 Month Performance9.25%1.35%8.29%10.68%1 Year Performance1,981.11%19.90%28.40%15.67% Virios Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRIVirios TherapeuticsN/A$5.08+6.7%$5.00-1.6%+1,804.0%$2.99MN/A-18.815AQSTAquestive Therapeutics1.9517 of 5 stars$3.70-0.5%$10.14+174.1%+50.9%$369.50M$57.56M-6.27160HUMAHumacyte1.5601 of 5 stars$2.16-5.3%$11.71+442.3%-64.7%$353.67M$1.57M-3.13150AMRNAmarin0.2904 of 5 stars$16.65-0.5%$12.00-27.9%+3.1%$346.43M$228.61M-4.57360Negative NewsPRTAProthena3.5788 of 5 stars$6.29-2.2%$31.50+400.8%-71.4%$346.38M$137.94M-3.02130BNTCBenitec Biopharma1.7634 of 5 stars$13.49+2.4%$23.83+76.7%+39.9%$345.72M$80K-8.9320High Trading VolumeHRTXHeron Therapeutics3.6224 of 5 stars$2.15-2.3%$5.00+132.6%-34.6%$335.64M$148.52M-35.83300Gap DownSNDLSNDL2.991 of 5 stars$1.24-2.4%$3.63+192.3%-26.5%$333.73M$671.81M-4.282,516Gap DownVORVor Biopharma3.873 of 5 stars$2.67+39.8%$5.63+110.8%+151.6%$333.64MN/A-1.62140High Trading VolumeAURAAura Biosciences2.5664 of 5 stars$6.16-6.1%$22.00+257.1%-21.1%$329.76MN/A-3.2450Positive NewsATXSAstria Therapeutics1.5933 of 5 stars$6.20+6.7%$30.00+383.9%-42.2%$327.88MN/A-3.3230 Related Companies and Tools Related Companies Aquestive Therapeutics Alternatives Humacyte Alternatives Amarin Alternatives Prothena Alternatives Benitec Biopharma Alternatives Heron Therapeutics Alternatives SNDL Alternatives Vor Biopharma Alternatives Aura Biosciences Alternatives Astria Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRI) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIRI Stock Alerts